Shares of Boston Scientific Corporation (NYSE:BSX) have earned an average recommendation of “Buy” from the twenty-one analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $30.39.

A number of research analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific Corporation in a report on Tuesday, October 3rd. BMO Capital Markets reiterated a “buy” rating and issued a $30.00 price target on shares of Boston Scientific Corporation in a report on Friday. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $34.00 price target on shares of Boston Scientific Corporation in a report on Monday, October 2nd. Stifel Nicolaus reiterated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific Corporation in a report on Monday, September 25th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of Boston Scientific Corporation in a report on Thursday, September 7th.

COPYRIGHT VIOLATION NOTICE: “Brokerages Set Boston Scientific Corporation (BSX) Target Price at $30.39” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/brokerages-set-boston-scientific-corporation-bsx-target-price-at-30-39/1631018.html.

In other Boston Scientific Corporation news, EVP Timothy A. Pratt sold 11,061 shares of Boston Scientific Corporation stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the sale, the executive vice president now owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP John Bradley Sorenson sold 2,100 shares of Boston Scientific Corporation stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $27.15, for a total value of $57,015.00. Following the sale, the senior vice president now directly owns 18,880 shares of the company’s stock, valued at approximately $512,592. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 531,297 shares of company stock valued at $15,144,095. 0.74% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of BSX. Guardian Life Insurance Co. of America lifted its holdings in shares of Boston Scientific Corporation by 0.9% in the 1st quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 49 shares during the period. Comerica Securities Inc. lifted its holdings in shares of Boston Scientific Corporation by 0.9% in the 2nd quarter. Comerica Securities Inc. now owns 11,478 shares of the medical equipment provider’s stock valued at $318,000 after buying an additional 99 shares during the period. ETRADE Capital Management LLC lifted its holdings in shares of Boston Scientific Corporation by 1.7% in the 2nd quarter. ETRADE Capital Management LLC now owns 10,079 shares of the medical equipment provider’s stock valued at $279,000 after buying an additional 171 shares during the period. Cleararc Capital Inc. lifted its holdings in shares of Boston Scientific Corporation by 0.8% in the 1st quarter. Cleararc Capital Inc. now owns 33,322 shares of the medical equipment provider’s stock valued at $829,000 after buying an additional 251 shares during the period. Finally, BB&T Corp lifted its holdings in shares of Boston Scientific Corporation by 2.8% in the 2nd quarter. BB&T Corp now owns 12,926 shares of the medical equipment provider’s stock valued at $359,000 after buying an additional 349 shares during the period. 90.44% of the stock is owned by institutional investors.

Shares of Boston Scientific Corporation (NYSE:BSX) traded up 0.03% during midday trading on Wednesday, reaching $29.44. The company had a trading volume of 3,383,917 shares. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $29.54. The firm’s 50 day moving average price is $28.65 and its 200-day moving average price is $27.17. The stock has a market capitalization of $40.40 billion, a price-to-earnings ratio of 52.67 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period last year, the business posted $0.27 EPS. The business’s revenue was up 6.2% compared to the same quarter last year. Equities research analysts expect that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.